Bristol-Myers Squibb Co (WBO:BMYS) Net Income From Continuing Operations : €-5,610 Mil (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Bristol-Myers Squibb Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Bristol-Myers Squibb Co's net income from continuing operations for the three months ended in Mar. 2024 was €-10,955 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was €-5,610 Mil.

Bristol-Myers Squibb Co Net Income From Continuing Operations Historical Data

The historical data trend for Bristol-Myers Squibb Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co Net Income From Continuing Operations Chart

Bristol-Myers Squibb Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

3,114.00

-7,393.89

6,207.39

5,989.68

7,372.68

Bristol-Myers Squibb Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial															2,117.38	1,917.07	1,812.16	1,615.75	-10,955.36

Bristol-Myers Squibb Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5,610 Mil.

Bristol-Myers Squibb Co (WBO:BMYS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (WBO:BMYS) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

BMYMP.PFD:USA BMY:USA BMY:Peru BMY:Mexico 1BMY:Italy BRMd:UK 0R1F:UK BRM:Germany BMYB34:Brazil BMY:Argentina

Address

430 East 29th Street, 14th Floor, New York, NY, USA, 10016

Website

https://www.bms.com

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.

Bristol-Myers Squibb Co (WBO:BMYS) Headlines

No Headlines